# US 2017/0281646 A1 · Steroid hormone pharmaceutical composition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0281646 A1
- Document ID: US20170281646A1
- Status: Published application
- Kind: A1
- Application number: 15/475,052
- Filed: 2017-03-30
- Published: 2017-10-05
- Earliest claimed: 2016-04-01
- Applicants: TherapeuticsMD, Inc.
- Inventors: PHILIP B. INSKEEP; PETER H.R. PERSICANER; ANNETTE SHADIACK; THORSTEINN THORSTEINSSON; FREDERICK D. SANCILIO; JASON D. LEGASSIE
- Web page: https://patentgrep.com/patent/US20170281646A1

## CPC

- A61K 31/57: substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K 9/107: Emulsions {; Emulsion preconcentrates; Micelles (composition of emulsions A61K47/00)}
- A61K 9/1075: {Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence)}
- A61K 9/4858: {Organic compounds}
- A61K 9/4866: {Organic macromolecular compounds}
- A61K 31/565: not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K 47/06: Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14)
- A61P 5/30: Oestrogens
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 13/00: Drugs for disorders of the urinary system
- A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 15/02: for disorders of the vagina
- A61P 19/10: for osteoporosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This disclosure provides a novel pharmaceutical composition for delivering steroid hormones, such as estradiol and progesterone, to a patient in need thereof.

## Claims

### Claim 1

A pharmaceutical composition suitable for administering estradiol and progesterone to a subject in need thereof, the pharmaceutical composition comprising estradiol, progesterone, a lipophilic surfactant system comprising a first lipophilic surfactant and a second lipophilic surfactant, wherein the first and second lipophilic surfactants are different from each other, a hydrophilic surfactant system comprising first and second hydrophilic surfactants, and an optional terpene, wherein the pharmaceutical composition is completely or substantially free of fractionated vegetable oils.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein the first lipophilic surfactant is a first partial triglyceride.

### Claim 3 (depends on 2)

The pharmaceutical composition of claim 2, wherein the second lipophilic surfactant is a second partial triglyceride.

### Claim 4 (depends on 3)

The pharmaceutical composition of claim 3, wherein the first and second partial triglycerides are selected from the group consisting of IMWITOR 988, IMWITOR 742, IMWITOR 308, CAPMUL MCM NF, CAPMUL 708G, and glyceryl dilaurate.

### Claim 5 (depends on 4)

The pharmaceutical composition of claim 4, wherein the first partial triglyceride is CAPMUL MCM NF and the second partial triglyceride is CAPMUL 708G.

### Claim 6 (depends on 5)

The pharmaceutical composition of claim 5, wherein the first hydrophilic surfactant is a polyoxyethylene sorbitan fatty acid derivative.

### Claim 7 (depends on 6)

The pharmaceutical composition of claim 6, wherein the polyoxyethylene sorbitan fatty acid derivative is TWEEN 20 or TWEEN 80.

### Claim 8 (depends on 6)

The pharmaceutical composition of claim 6, wherein the second hydrophilic surfactant is a castor oil or hydrogenated castor oil ethoxylate.

### Claim 9 (depends on 8)

The pharmaceutical composition of claim 8, wherein the castor oil or hydrogenated castor oil ethoxylate is CREMOPHOR EL, CREMOPHOR RH40, ETOCAS 40, CRODURET 60, or KOLLIPHOR HS 15.

### Claim 10 (depends on 9)

The pharmaceutical composition of claim 9, wherein the castor oil or hydrogenated castor oil ethoxylate is CREMOPHOR RH40.

### Claim 11 (depends on 1)

The pharmaceutical composition of claim 1, wherein the second hydrophilic surfactant is LABRASOL, TPGS, or ascorbyl-6 palmitate.

### Claim 12 (depends on 11)

The pharmaceutical composition of claim 11, wherein the second hydrophilic surfactant is TPGS.

### Claim 13 (depends on 1)

The pharmaceutical composition of claim 1, wherein the terpene is not optional and is selected from the group consisting of d-limonene, menthene, menthol, phellandrene, terpinene, or terpineol.

### Claim 14 (depends on 13)

The pharmaceutical composition of claim 13, wherein the terpene is d-limonene.

### Claim 15 (depends on 1)

The pharmaceutical composition of claim 1, wherein the estradiol and the progesterone are both solubilized.

### Claim 16 (depends on 1)

The pharmaceutical composition of claim 1, wherein the estradiol and the progesterone are both fully solubilized.

### Claim 17 (depends on 1)

The pharmaceutical composition of claim 1, wherein the pharmaceutical composition forms micelles.

### Claim at position 18

-35. (canceled)

### Claim 36 (depends on 1)

A method of treating a symptom of menopause, the method comprising administering to a subject in need thereof a pharmaceutical composition according to claim 1.

### Claim 37 (depends on 36)

The method of claim 36, wherein the symptom of menopause is selected from the group consisting of hot flushes, hot flashes, vaginal dryness, night sweats, urinary tract infections, loss of libido, heart disease, or osteoporosis.

### Claim at position 21

-39. (canceled)

### Claim 40

A pharmaceutical composition suitable for administering estradiol and progesterone to a subject in need thereof, the pharmaceutical composition comprising estradiol, progesterone, a lipophilic surfactant system comprising a first lipophilic surfactant and a second lipophilic surfactant, wherein the first and second lipophilic surfactants are different from each other, a hydrophilic surfactant system comprising first and second hydrophilic surfactants, and an optional terpene, wherein the pharmaceutical composition is completely or substantially free of fractionated vegetable oils, wherein both the estradiol and the progesterone are solubilized in the pharmaceutical composition, and wherein the pharmaceutical composition forms micelles.

### Claim at position 23

-43. (canceled)
